Table of Contents
A panel held by the World Health Organization has called for a Phase III trial of the Zaire Ebolavirus vaccine Ervebo to be investigated against the current Bundibugyo strain, marking a significant step toward the Ervebo Phase III Bundibugyo trial in response to an active outbreak with no existing vaccine option.
How the Ervebo Phase III Bundibugyo Trial Decision Was Reached
In a WHO Technical Advisory Group on candidate vaccine prioritisation, or TAG-CVP, meeting held on July 31, members were, with one exception, unanimously of the view that Ervebo should be prioritised for inclusion in a Phase III trial against the strain causing the current outbreak.
Why Ervebo Could Skip an Initial Phase II Evaluation
There are no vaccines available against the Bundibugyo strain, and experts therefore concluded that considering the wealth of reactogenicity and immunogenicity data and population-wide safety data available for Ervebo, it could enter a Phase III trial without an initial Phase II evaluation. They did add, however, that this study should not preclude the later inclusion of a Bundibugyo-specific vaccine candidate, should one become available and be considered suitable for evaluation in the current outbreak.
The Evidence Behind the Ervebo Phase III Bundibugyo Trial Recommendation
The WHO panel came to this decision based on a number of research papers and preclinical studies of Ervebo. They did note certain limitations with the research, though, including that some was not peer-reviewed, and that research-grade rVSV-EBOV material was used, rather than licensed Ervebo product, in certain studies. Despite this, all four studies showed a low level of cross-reacting binding antibodies to Bundibugyo induced by Ervebo.
Why Ervebo’s Existing Approval Status Matters
Another benefit of Ervebo, which the panel unanimously agreed on, is that there were no safety concerns regarding its use in a clinical research study, as the vaccine is already approved by regulatory agencies globally and has been given to hundreds of thousands of people in Africa. The WHO also has a stockpile of the vaccine, meaning a rollout would be easier.
Managing Expectations Around This Ervebo Phase III Bundibugyo Trial
The panel caveated its recommendation, adding that expectations over the potential efficacy need to be managed about its likely protective effect if used in a Phase III ring vaccination trial, as efficacy against symptomatic disease and transmission may not be high, whereas protection against a fatal outcome may be achieved.
A Distinction With Real Clinical Implications
This nuanced framing, where a vaccine might meaningfully reduce mortality even if it doesn’t strongly prevent infection or transmission, reflects the kind of pragmatic risk-benefit calculation WHO panels often face when repurposing an existing vaccine against a related but genetically distinct viral strain during an active emergency.
Parallel Research Efforts Alongside the Ervebo Phase III Bundibugyo Trial
Earlier in August, Moderna initiated a Phase I trial of its mRNA Ebola vaccine for the Bundibugyo variant. The first-in-human trial, approved by Health Canada, will test Moderna’s vaccine candidate, mRNA-1469, at three sites in Canada, evaluating safety, tolerability, and immunogenicity in healthy adult participants, with plans to enroll approximately 80 participants.
WHO’s Parallel Treatment Trial
WHO has also initiated a study to investigate treatments for those infected with the virus. Through a clinical trial dubbed PARTNERS, WHO and its international partners will evaluate the potential of two antiviral therapies, alone or in combination, for treating Bundibugyo virus disease: Gilead Sciences’ remdesivir and Mapp Biopharmaceutical’s investigational double antibody-based therapy MBP134, with efforts beginning in the Democratic Republic of Congo.
The Scale of the Outbreak Behind the Ervebo Phase III Bundibugyo Trial
Bundibugyo is one of the viruses that can cause Ebola disease and has been responsible for the active outbreak in the DRC. Although vaccines are available against Zaire ebolavirus, no vaccine is currently approved to protect against disease caused by Bundibugyo. The current outbreak was declared a Public Health Emergency of International Concern by WHO and a Public Health Emergency of Continental Security by the Africa Centres for Disease Control and Prevention, and has already caused more than 3,000 confirmed cases and more than 1,400 deaths, making it one of the largest filovirus outbreaks in history.
Why This Scale Adds Urgency
Given the outbreak’s status as one of the largest filovirus outbreaks on record, the combination of the Ervebo Phase III trial, Moderna’s Phase I mRNA candidate, and the PARTNERS antiviral treatment study represents a multi-pronged international response addressing both prevention and treatment simultaneously.
What This Ervebo Phase III Bundibugyo Trial Means Going Forward
With TAG-CVP’s near-unanimous recommendation now in place and WHO’s existing Ervebo stockpile positioned to ease rollout logistics, this trial could move relatively quickly compared to developing an entirely new vaccine candidate from scratch. Given the panel’s explicit caution that efficacy against symptomatic disease and transmission may prove limited even if mortality protection is achieved, public health officials and trial investigators will need to carefully communicate these tempered expectations to affected communities and healthcare workers in the DRC.
What to Watch Going Forward
As the Phase III ring vaccination trial moves forward alongside Moderna’s Phase I mRNA candidate and WHO’s PARTNERS antiviral study, researchers and public health officials will likely watch closely for early efficacy signals that could clarify how much protection Ervebo actually offers against the Bundibugyo strain in real-world outbreak conditions. Given the outbreak’s severity, with more than 1,400 deaths already recorded, the outcome of this Ervebo Phase III Bundibugyo trial could significantly shape both the immediate outbreak response and longer-term vaccine stockpile strategy for future Bundibugyo-driven emergencies.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
